Let’s examine the information gathered:
1. On Wednesday, Aug 19, 2026, Moderna (MRNA) announced landmark positive Phase 3 INTerpath-001 trial results with partner Merck (MRK) for their personalized mRNA cancer vaccine, intismeran autogene combined with Keytruda for melanoma. That drove an extraordinary multi-day rally where the stock jumped over 120%-177% in a few sessions to multi-year high around $175-$176.
2. Over the following trading sessions, especially on Monday, Aug 24, 2026, the stock pulled back dramatically (-5.13% to -8% range depending on intraday points, taking a breather/profit taking).
3. Reasons for the down move on August 24, 2026:
– Profit-taking following a multi-day massive surge (traders booking quick profits after a…